FDA approves use of combo for hepatitis C in children

12/14/2008 | Winston-Salem Journal (N.C.)

Schering-Plough obtained FDA clearance to market a regimen that combines Rebetol -- an antiviral drug -- with Pegintron -- a bioengineered version of an immune-system protein called interferon -- to treat hepatitis C in children ages 3 to 17. The two-drug therapy offers extended effectiveness with the aid of pegylation, a technology used in Pegintron that allows it to remain in the blood longer.

View Full Article in:

Winston-Salem Journal (N.C.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC